<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01538316</url>
  </required_header>
  <id_info>
    <org_study_id>ZEM 21 AII</org_study_id>
    <nct_id>NCT01538316</nct_id>
  </id_info>
  <brief_title>Prostate Cancer Prevention Trial With Quercetin and Genistein</brief_title>
  <acronym>QUERGEN</acronym>
  <official_title>Clinical Trial on the Effectiveness of the Flavonoids Genistein and Quercetin in Men With Rising Prostate-specific Antigen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Hohenheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Quercegen Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Hohenheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the randomized controlled double-blind crossover trial is to evaluate the
      effectiveness of two dietary supplements containing polyphenolic phytochemicals (isoflavonoid
      genistein and flavonoid quercetin) in comparison with placebo on the rate of increase in
      prostate-specific antigen (PSA). In addition, secondary objective is to evaluate the
      incidence of prostate cancer and to analyze malondialdehyde and protein carbonyle as
      indicators of the oxidative status.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prostate cancer (PC) is the most frequently occurring cancer in men. Its clinical incidence
      and mortality rates vary geographically, being much lower in Asia than in Western countries.
      Notably, latent PCs seem to be equally distributed, thus supporting the hypothesis, that
      environmental factors may be important in prostate cancer progression. Moreover,
      epidemiological evidence strongly supports the concept that the incidence of clinical
      prostate cancer depends on lifestyle factors, mainly related to diet. The isoflavone
      genistein and the flavonoid quercetin have been identified as likely preventive candidates.
      The aim of the intended clinical trial is to evaluate the hypothesized effectiveness of
      polyphenolic phytochemicals with highly purified dietary supplements in patients at high risk
      of clinical PC and without systemic treatment. This will provide data, which serve as an
      important pre-requesite for targeted dietary interventions using alternative medicine as
      preventive measures in men with latent PC.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in prostate-specific antigen</measure>
    <time_frame>Every three months (over a period of 18 months)</time_frame>
    <description>Effect on the slope of the regression line though all log2-transformed PSA measurements during the concerned period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prostate cancer incidence</measure>
    <time_frame>over the whole study period of 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quercetin- and genistein blood concentrations</measure>
    <time_frame>Every three months (over a period of 18 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IPSS (International Prostate Symptom Score)</measure>
    <time_frame>Every three months (over a period of 18 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Every three months (over a period of 18 months)</time_frame>
    <description>SF 36</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Primary Prevention of Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Quercetin supplement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Genistein supplement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Quercetin supplement</intervention_name>
    <description>500 mg/d quercetin (+ vitamin C + folic acid + vitamin B3) over a period of six months; crossover design (6 month-periods): followed by genistein and placebo supplement.</description>
    <arm_group_label>Quercetin supplement</arm_group_label>
    <other_name>Q-Force Chew</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Genistein supplement</intervention_name>
    <description>100 mg/d genistein (+ vitamin C + folic acid + vitamin B3) over a period of six months; crossover design (6 month-periods): followed by placebo and quercetin supplement.</description>
    <arm_group_label>Genistein supplement</arm_group_label>
    <other_name>Q-Force Chew</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>vitamin C + folic acid + vitamin B3 over a period of six months; crossover design (6 month-periods): followed by quercetin and genistein supplement.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Q-Force Chew</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with deviant PSA constellation:

               1. Patients with PSA 2,5 - 4 μg/l and free PSA/total PSA &lt; 15 %

               2. Patients with PSA &gt; 4 μg/l with negative punch biopsy of the prostate

                  Exclusion Criteria:

          -  chronic liver diseases, impaired kidney function

          -  inflammatory diseases of the urogenital tract

          -  history of malignancy of any organ system, treated or untreated, within the past three
             years whether or not there is evidence of local recurrence or metastases

          -  therapy with Doxazosin, Dutaserid and/ or Finasterid, Testosteron and other hormonal
             active medicaments

          -  inflammatory bowel diseases

          -  malabsorption/-digestion

          -  hypersensitivity/allergy to soy

          -  phytotherapy or intake of dietary supplements

          -  smoker

          -  abnormal clinical laboratory values at baseline

          -  participation in any other trial with an investigational new drug

          -  inability to sign informed consent
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan C Bischoff, MD, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>University of Hohenheim</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arnulf Stenzl, MD, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Dept. of Urology, University Hospital Tübingen, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antje Damms Machado, dipl. troph.</last_name>
    <email>antje.machado@uni-hohenheim.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Nutritional Medicine, University of Hohenheim</name>
      <address>
        <city>Stuttgart</city>
        <zip>70599</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antje Damms Machado, dipl. troph.</last_name>
      <email>antje.machado@uni-hohenheim.de</email>
    </contact>
    <investigator>
      <last_name>Stephan C Bischoff, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Urology, University Hospital Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Aufderklamm, MD</last_name>
    </contact>
    <investigator>
      <last_name>Arnulf Stenzl, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2012</study_first_submitted>
  <study_first_submitted_qc>February 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2012</study_first_posted>
  <last_update_submitted>May 13, 2012</last_update_submitted>
  <last_update_submitted_qc>May 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Hohenheim</investigator_affiliation>
    <investigator_full_name>Stephan C. Bischoff, MD, Professor</investigator_full_name>
    <investigator_title>MD, Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>dietary supplements</keyword>
  <keyword>quercetin</keyword>
  <keyword>genistein</keyword>
  <keyword>prostate-specific antigen</keyword>
  <keyword>oxidative Status</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Genistein</mesh_term>
    <mesh_term>Quercetin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

